Sepsis-The Final Common Pathway to Death From Multiple Organ Failure in Infection.

Crit Care Med

Medical Affairs, BC Children's Hospital and Sunny Hill Health Centre, BCCH and UBC Global Child Health, Vancouver, BC, Canada; Department of Pediatrics, Global Sepsis Alliance; and Department of Paediatrics and Emergency Medicine, University of British Columbia, Child and Family Research Institute, Vancouver, BC, Canada; Critical Care, United Kingdom, Department of Critical Care and Anesthesia, Global Sepsis Alliance; and UK Sepsis Trust; Division of Infectious Diseases and Center for Experimental and Molecular Medicine, Department of Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; Intensive Care, Royal North Shore Hospital, Sydney, NSW, Australia; and Department of Critical Care and Anesthesia, International Sepsis Forum and Global Sepsis Alliance; Anaesthesiology and Intensive Care, Jena University Hospital, Jena, Germany; and Department of Critical Care and Anesthesia, Global Sepsis Alliance.

Published: June 2016

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCM.0000000000001582DOI Listing

Publication Analysis

Top Keywords

sepsis-the final
4
final common
4
common pathway
4
pathway death
4
death multiple
4
multiple organ
4
organ failure
4
failure infection
4
sepsis-the
1
common
1

Similar Publications

Article Synopsis
  • Antimicrobial resistance (AMR) is a significant global health issue in the 21st century, affecting the burden of disease and mortality linked to bacterial infections across various regions.
  • A comprehensive study was conducted to assess the impact of AMR from 1990 to 2021, analyzing data from 204 countries on deaths and disability-adjusted life years (DALYs) related to 22 pathogens and 84 pathogen-drug combinations.
  • The researchers employed statistical modeling and extensive datasets to estimate AMR's burden, even in areas lacking direct data, considering multiple factors such as sepsis-related deaths and antibiotic resistance rates.
View Article and Find Full Text PDF

Background: Sepsis is a prevalent and severe medical condition which is frequently observed in the intensive care unit (ICU). Although numerous biomarkers have been identified to predict the prognosis of sepsis, the lactate dehydrogenase to albumin ratio (LDH/ALB ratio) has not been extensively investigated. The principal objective of this study is to assess the relationship between LDH/ALB ratio and all-cause mortality in patients with sepsis.

View Article and Find Full Text PDF
Article Synopsis
  • The Society of Critical Care Medicine Pediatric Sepsis Definition Task Force worked on creating and validating new clinical criteria for identifying pediatric sepsis and septic shock, focusing on organ dysfunction metrics.
  • This research involved a large-scale international study across 10 healthcare systems, collecting data on nearly 3.6 million children over nine years to derive and test the new criteria.
  • The final scoring system, named the Phoenix Sepsis Score, was developed from a 4-organ-system model, demonstrating varying effectiveness in predicting mortality through different performance metrics during validation.
View Article and Find Full Text PDF

Importance: Meropenem is a widely prescribed β-lactam antibiotic. Meropenem exhibits maximum pharmacodynamic efficacy when given by continuous infusion to deliver constant drug levels above the minimal inhibitory concentration. Compared with intermittent administration, continuous administration of meropenem may improve clinical outcomes.

View Article and Find Full Text PDF

Effect of an Herbal-Based Injection on 28-Day Mortality in Patients With Sepsis: The EXIT-SEP Randomized Clinical Trial.

JAMA Intern Med

July 2023

Jiangsu Provincial Key Laboratory of Critical Care Medicine, Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu, China.

Article Synopsis
  • Recent research has indicated that Xuebijing injection (XBJ), an herbal intravenous treatment, may lower death rates in sepsis patients.
  • The EXIT-SEP trial, involving 1817 patients in 45 intensive care units, aimed to assess the effect of XBJ versus a placebo on 28-day mortality in sepsis patients.
  • Results showed a significant reduction in mortality for those receiving XBJ compared to placebo, meaning XBJ could be a promising treatment option for sepsis.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!